
|Videos|May 11, 2022
Frontline Trials for BRAF-Mutant Metastatic Melanoma: Relatlimab Plus Nivolumab
Author(s)Michael Atkins, MD, Evan Lipson, MD
Data from the RELATIVITY-047 trial, which evaluated relatlimab plus nivolumab in untreated, advanced melanoma were reviewed and clinical implications of these data were discussed.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on OncLive
1
Daraxonrasib Plus Gemcitabine/Nab-Paclitaxel Generates Durable Responses in First-Line Metastatic PDAC
2
TroFuse-015 Meets Primary OS End Point With Sac-TMT in Third-Line or Later Gastroesophageal Adenocarcinoma
3
Dr Iyengar on Oral SERD Implementation in Early-Stage HR+ Breast Cancer
4
Dr Gutierrez on Considerations for Investigating SAR445877 in MSS CRC
5



